These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3819811)

  • 1. Effect of calcium channel blockers on human CFU-GM with cytotoxic drugs.
    Fine RL; Koizumi S; Curt GA; Chabner BA
    J Clin Oncol; 1987 Mar; 5(3):489-95. PubMed ID: 3819811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of calcium antagonists on anti-cancer drug toxicity to haematopoietic progenitor cells in normal human bone marrow.
    Nakarai T; Koizumi S
    Leuk Res; 1990; 14(5):401-5. PubMed ID: 2345465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.
    Yalowich JC; Zucali JR; Gross M; Ross WE
    Cancer Res; 1985 Oct; 45(10):4921-4. PubMed ID: 3861238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired vs innate multidrug resistance and the effect of calcium channel blockers.
    Tsuruo T
    Prog Clin Biol Res; 1986; 223():203-16. PubMed ID: 3468516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
    Vilpo J; Koski T; Vilpo L
    Haematologica; 2000 Aug; 85(8):806-13. PubMed ID: 10942926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil enhances antitumor activity without increasing myeloid toxicity.
    Morrow M; Wait RB; Rosenthal RA; Gamelli RL
    Surgery; 1987 Jan; 101(1):63-8. PubMed ID: 3798329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in the growth and cycling status of granulocyte-monocyte colony-forming units (CFU-GM) in rats injected single doses of aflatoxin B1.
    Cukrová V; Kurita N; Akao M
    Neoplasma; 1992; 39(2):93-6. PubMed ID: 1528314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to adriamycin and VP16.
    Smith MA; Merry S; Smith JG; Kaye SB
    Br J Cancer; 1988 Jun; 57(6):576-8. PubMed ID: 3408645
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct interaction between verapamil and doxorubicin causes the lack of reversal effect of verapamil on P-glycoprotein mediated resistance to doxorubicin in vitro using L1210/VCR cells.
    Breier A; Drobná Z; Barancík M
    Neoplasma; 1998; 45(4):248-53. PubMed ID: 9890669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
    Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
    Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state.
    Minderman H; Linssen P; van der Lely N; Wessels J; Boezeman J; de Witte T; Haanen C
    Leukemia; 1994 Mar; 8(3):382-7. PubMed ID: 8127143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vitro.
    Dessypris EN; Brenner DE; Hande KR
    Cancer Treat Rep; 1986 Apr; 70(4):487-90. PubMed ID: 3698042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of novel anthracycline derivatives towards normal myeloid bone marrow progenitor cells (CFU-GM) is not increased by verapamil.
    Busch FW; Schmittele U; Ehninger G
    Blut; 1990 Apr; 60(4):219-22. PubMed ID: 2337680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement.
    Naito M; Tsuruo T
    Cancer Res; 1989 Mar; 49(6):1452-5. PubMed ID: 2924298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite effect of tumor necrosis factor alpha on granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-dependent growth of normal and leukemic hemopoietic progenitors.
    Piacibello W; Sanavio F; Severino A; Morelli S; Vaira AM; Stacchini A; Aglietta M
    Cancer Res; 1990 Aug; 50(16):5065-71. PubMed ID: 1696165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of deoxycytidine on 2-chloro-deoxyadenosine-mediated growth inhibition of normal human erythroid and myeloid progenitor cells.
    Bilgeri R; Petzer AL; Zilian U; Geisen FH; Schirmer M; Haun M; Konwalinka G
    Exp Hematol; 1993 Mar; 21(3):432-7. PubMed ID: 8095026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated marrow recovery following total-body irradiation after treatment with vincristine, lithium or combined vincristine-lithium.
    Johnke RM; Abernathy RS
    Int J Cell Cloning; 1991 Jan; 9(1):78-88. PubMed ID: 2010658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
    Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
    J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.